Surgery with intraoperative botulinum toxin-A injection for the treatment of large-angle horizontal strabismus: a pilot study

Minguini, Nilza; Carvalho, Keila Monteiro de; Bosso, Fábio L. S.; Hirata, Fábio Endo; Kara‐José, Newton

doi:10.6061/clinics/2012(03)13

Cited by 15 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over half of the studies (52%) discussed outcome measures following surgical interventions for strabismus, most commonly muscle surgery (45%) [5, 42, 55, 56, 60, 61, 64–72] and less for botulinum toxin injection [2, 54]. Muscle surgery and botulinum toxin injection were both combined in one study [63]. In contrast, non-surgical or conservative treatments were evaluated in five of included studies (15%) [52, 57, 73–75].…”

Section: Resultsmentioning

confidence: 99%

“…This was reported as “motor alignment” or “angle of deviation” in 26/33 studies. This was further described to be measured “at near and distance” in seven studies out of these [4, 5, 63, 66, 70, 71, 77].…”

Section: Resultsmentioning

confidence: 99%

“…In 12 studies alignment was measured using “prism alternate cover test PACT” [4, 5, 54, 58, 59, 63, 67, 70, 71, 74, 77, 78] and /or with “simultaneous prism cover test SPCT” in eight studies [4, 53, 63, 66, 74, 75, 77, 79]. “Cover test” was reported in five studies [2, 42, 73, 74, 79], “Synoptophore” in four [2, 4, 42, 53] and “Hirschberg test” in three [54, 73, 79].…”

Section: Resultsmentioning

confidence: 99%

“…“Cover test” was reported in five studies [2, 42, 73, 74, 79], “Synoptophore” in four [2, 4, 42, 53] and “Hirschberg test” in three [54, 73, 79]. Krimsky test was reported as an alternative test in subjects with poor cooperation in one study [54], when cover tests are not applicable [63] or in cases with poor vision (worse than 20/200) in one RCT [60].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures

2019

View full text Add to dashboard Cite

BackgroundCore Outcome Sets (COS) are defined as the minimum sets of outcomes that should be measured and reported in all randomised controlled trials to facilitate combination and comparability of research. The aim of this review is to produce an item bank of previously reported outcome measures from published studies in amblyopia, strabismus and ocular motility disorders to initiate the development of COS.MethodsA review was conducted to identify articles reporting outcome measures for amblyopia, strabismus and ocular motility disorders. Using systematic methods according to the COMET handbook we searched key electronic bibliographic databases from 1st January 2011 to 27th September 2016 using MESH terms and alternatives indicating the different subtypes of amblyopia, strabismus and ocular motility disorders in relation to treatment outcomes and all synonyms. We included Cochrane reviews, other systematic reviews, controlled trials, non-systematic reviews and retrospective studies. Data was extracted to tabulate demographics of included studies, primary and secondary outcomes, methods of measurement and their time points.ResultsA total of 142 studies were included; 42 in amblyopia, 33 in strabismus, and 68 in ocular motility disorders (one study overlap between amblyopia and strabismus). We identified ten main outcome measure domains for amblyopia, 14 for strabismus, and ten common “visual or motility” outcome measure domains for ocular motility disorders. Within the domains, we found variable nomenclature being used and diversity in methods and timings of measurements.ConclusionThis review highlights discrepancies in outcome measure reporting within published literature for amblyopia, strabismus and ocular motility and it generated an item bank of the most commonly used and reported outcome measures for each of the three conditions from recent literature to start the process of COS development. Consensus among all stakeholders including patients and professionals is recommended to establish a useful COS.Electronic supplementary materialThe online version of this article (10.1186/s12886-019-1055-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures

2019

View full text Add to dashboard Cite

show abstract

“…8 The therapeutic use of BoNT/A in ophthalmology is mainly for the treatment of essential blepharospasm, strabismus correction, chronic dry eye syndrome, congenital nystagmus, facial paralysis, lacrimal hypersecretion syndromes, eyelid retraction, entropion, and for the production of protective ptosis. 1,2,9 In this last case, BoNT/A when applied into the levator palpebral superioris muscle promotes ptosis with a temporary covering of the cornea, thus producing the same protective effect of some routine surgical procedures such as tarsorrhaphy. [10][11][12][13][14] The only published study describing the use of BoNT/A in veterinary ophthalmology refers to a case in which the toxin was successfully used during 3 years for the treatment of a possible essential blepharospasm in a dog.…”

Section: Introductionmentioning

confidence: 94%

Evaluation of the Efficacy and Safety of Botulinum Toxin Type A to Induce Temporary Ptosis in Dogs

Bittencourt

Vasconcellos

Bittencourt

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

Botulinum toxin for the treatment of strabismus

Rowe

Noonan

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Most published literature on the use of botulinum toxin in the treatment of strabismus consists of retrospective studies, cohort studies or case reviews. Although these provide useful descriptive information, clarification is required as to the effective use of botulinum toxin as an independent treatment modality. Six RCTs on the therapeutic use of botulinum toxin in strabismus, graded as low and very low-certainty evidence, have shown varying responses. These include a lack of evidence for effect of botulinum toxin on reducing visual symptoms in acute sixth nerve palsy, poor response in people with horizontal strabismus without binocular vision, similar or slightly reduced achievement of successful ocular alignment in children with esotropia and potential increased achievement of successful ocular alignment where surgery and botulinum toxin are combined. Further high quality trials using robust methodologies are required to compare the clinical and cost effectiveness of various forms of botulinum toxin (e.g. Dysport, Xeomin, etc), to compare botulinum toxin with and without adjuvant solutions and to compare botulinum toxin to alternative surgical interventions in strabismus cases with and without potential for binocular vision.

show abstract

Surgery with intraoperative botulinum toxin-A injection for the treatment of large-angle horizontal strabismus: a pilot study

Cited by 15 publications

References 22 publications

Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures

Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures

Evaluation of the Efficacy and Safety of Botulinum Toxin Type A to Induce Temporary Ptosis in Dogs

Botulinum toxin for the treatment of strabismus

Contact Info

Product

Resources

About